EUCTR2020-001170-29-Outside-EU/EEA进行中（未招募）1 期
A Phase 3, Open-label Clinical Study to Evaluate the Immunogenicity and Safety of 9vHPV Vaccine, in Japanese Boys and Girls, 9 to 15 Years of Age.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Is Japanese male or female.
- •Is aged at the time of providing the documented informed consent (inclusive): (3-dose boy arm) male from 9 years to 15 years old, (2-dose boy arm) male from 9 years to 14 years old, or (2-dose girl arm) female from 9 years to 14 years old.
- •Has a legally acceptable representative who can read, understand and complete the vaccination report card (VRC).
- •Has not yet had coitarche and does not plan on becoming sexually active during the Day 1 through Month 7
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 314
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Has a fever (defined as oral temperature =37.5°C) within the 24-hour period prior to the Day 1 visit.
- •Has a history of severe allergic reaction that required medical intervention.
- •Is allergic to any vaccine component, including aluminum, yeast, or Benzonase™.
- •Has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
- •Is currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other auto immune condition.
- •Has a history of splenectomy.
- •Has a history of genital warts or positive test for human papillomavirus (HPV).
- •Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within 12 months) of drug or alcohol abuse or dependence at the discretion of the investigator. .
- •Has received within 12 months prior to enrollment, is receiving, or plans to receive during Day 1 through Month 7 of the study, any study-prohibited concomitant immunosuppressive therapy .
- •Has received within the 3 months prior to the Day 1 vaccination, is receiving, or plans to receive during Day 1 through Month 7 of the study, any immune globulin product or blood-derived product other than intravenous gamma globulin (IVIG).
- •Has received inactivated or recombinant vaccines within 14 days prior to Day 1 vaccination or receipt of live vaccines within 28 days prior to Day 1 vaccination.
- •Has previously received a marketed HPV vaccine or has participated in a clinical trial for any HPV vaccine (receiving either active agent or placebo).
- •Is concurrently enrolled in other clinical studies of investigational agents.
- •Is unlikely to adhere to the study procedures, keep appointments, or is planning to permanently relocate from the area prior to the completion of the study or to leave for an extended period when study visits would need to be scheduled.
- •Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.
研究者
相似试验
进行中（未招募）
3 期
Phase 3 Study for Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Boys and GirlsJPRN-jRCT2031210080Tanaka Yoshiyuki300
进行中（未招募）
1 期
A study to assess the usefulness of fluciclovine (18F) PET/CT in patients with rising PSA after treatment of prostate cancerProstate cancer with biochemical recurrence after radical treatmentMedDRA version: 20.0 Level: PT Classification code 10036911 Term: Prostate cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000625-37-GBBlue Earth Diagnostics Limited180
招募中
3 期
Zimberelimab and domvanalimab in combination with chemotherapy versus pembrolizumab with chemotherapy in patients with untreated metastatic non-small cell lung canceron-small Cell Lung CancerJPRN-jRCT2061230073Ali Nasermoaddeli50
进行中（未招募）
1 期
MK-5172/MK-8742 vs Sofosbuvir/PR in HCV GT1, 4 or 6 InfectioMedDRA version: 17.1 Level: LLT Classification code 10019751 Term: Hepatitis C virus System Organ Class: 100000004848Hepatitis CEUCTR2014-003836-38-NOMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.257
进行中（未招募）
不适用
MK-5172/MK-8742 vs Sofosbuvir/PR in HCV GT1, 4 or 6 InfectioMedDRA version: 17.1Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848Hepatitis CEUCTR2014-003836-38-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.256